- Home
- DCTH vs LAC Comparison
DCTH vs LAC Comparison
Compare DCTH & LAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- LAC
- Stock Information
- Founded
- DCTH 1988
- LAC 2023
- Country
- DCTH United States
- LAC Canada
- Employees
- DCTH N/A
- LAC N/A
- Industry
- DCTH Medical/Dental Instruments
- LAC Metal Mining
- Sector
- DCTH Health Care
- LAC Basic Materials
- Exchange
- DCTH Nasdaq
- LAC Nasdaq
- Market Cap
- DCTH 630.4M
- LAC 617.3M
- IPO Year
- DCTH N/A
- LAC N/A
- Fundamental
- Price
- DCTH $16.30
- LAC $2.65
- Analyst Decision
- DCTH Strong Buy
- LAC Hold
- Analyst Count
- DCTH 4
- LAC 6
- Target Price
- DCTH $24.00
- LAC $4.29
- AVG Volume (30 Days)
- DCTH 610.5K
- LAC 4.6M
- Earning Date
- DCTH 05-08-2025
- LAC 05-15-2025
- Dividend Yield
- DCTH N/A
- LAC N/A
- EPS Growth
- DCTH N/A
- LAC N/A
- EPS
- DCTH N/A
- LAC N/A
- Revenue
- DCTH $53,850,000.00
- LAC N/A
- Revenue This Year
- DCTH $141.47
- LAC N/A
- Revenue Next Year
- DCTH $49.31
- LAC N/A
- P/E Ratio
- DCTH N/A
- LAC N/A
- Revenue Growth
- DCTH 1068.87
- LAC N/A
- 52 Week Low
- DCTH $6.33
- LAC $2.02
- 52 Week High
- DCTH $18.23
- LAC $5.20
- Technical
- Relative Strength Index (RSI)
- DCTH 58.68
- LAC 38.42
- Support Level
- DCTH $15.73
- LAC $2.66
- Resistance Level
- DCTH $17.29
- LAC $2.81
- Average True Range (ATR)
- DCTH 0.96
- LAC 0.13
- MACD
- DCTH -0.08
- LAC -0.04
- Stochastic Oscillator
- DCTH 50.58
- LAC 6.03
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, that is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass recently began construction and is expected to begin production in the late 2020s. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.